CRISPR/Cas9 from bench to bedside: what clinicians need to know before application?

In October 2020, Dr. Emmanuelle Charpentier and Dr. Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering work in precise genome editing using the CRISPR technology. Although CRISPR technology has developed rapidly in the last decade, there are still many uncertainties before eventua...

Full description

Saved in:
Bibliographic Details
Published inMilitary medical research Vol. 7; no. 1; pp. 61 - 3
Main Authors Li, Zi-Qing, Li, Chao-Hong
Format Journal Article
LanguageEnglish
Published England BioMed Central 08.12.2020
BMC
Subjects
CRISPR
CRISPR-Cas Systems
CRISPR/Cas9
Deoxyribonucleic acid
Design
DNA
Embryos
Ethical concerns
Ethics
Gene therapy
Genetic engineering
Genome editing
Genomes
Hospitals
Humans
Joint surgery
Laboratories
Letter to the Editor
Nobel prize
Nobel prizes
Off-target effect
Point-of-Care Systems - trends
China
Nobel prize
Off-target effect
Genome editing
CRISPR/Cas9
Ethical concerns
Online AccessGet full text

Cover

More Information
Summary:In October 2020, Dr. Emmanuelle Charpentier and Dr. Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering work in precise genome editing using the CRISPR technology. Although CRISPR technology has developed rapidly in the last decade, there are still many uncertainties before eventual use in clinical settings. In this mini review, we summarize the current efforts in addressing the limitations of CRISPR technology and future directions.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
ObjectType-Article-2
content type line 23
ISSN:2054-9369
2095-7467
2054-9369
DOI:10.1186/s40779-020-00292-2